Lee's Pharmaceutical Holdings Ltd
HKEX:950
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.19
2.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| HK |
|
Lee's Pharmaceutical Holdings Ltd
HKEX:950
|
918.6m HKD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
541.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
278.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
223.2B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.1B EUR |
Loading...
|
Market Distribution
| Min | -239 513 300% |
| 30th Percentile | -12.9% |
| Median | 0.5% |
| 70th Percentile | 5.3% |
| Max | 203 056% |
Other Profitability Ratios
Lee's Pharmaceutical Holdings Ltd
Glance View
Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture and sale of pharmaceutical products. The firm operates through two segments. Proprietary Products segment is engaged in the manufacture and sales of self-developed pharmaceutical products. Its proprietary products include Yallaferon, Livaracine and Slounase, among others. Licensed-in Products segment is engaged in the trading of licensed-in pharmaceutical products. Its licensed-in products include Ferplex and Zanidip, among others. The Company’s products are for cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology, among others. The firm mainly operates businesses in China and Hong Kong.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Lee's Pharmaceutical Holdings Ltd is 6.8%, which is above its 3-year median of 4.7%.
Over the last 3 years, Lee's Pharmaceutical Holdings Ltd’s Net Margin has increased from -10.5% to 6.8%. During this period, it reached a low of -10.5% on May 30, 2022 and a high of 6.8% on Jul 30, 2025.